,

Standardby Admin0 Comments

Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.   https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-sun-pharma-to-conduct-clinical-trial-of-pancreatitis-drug-in-covid-19-patients/articleshow/76089435.cms

0
,

Standardby Admin0 Comments

The 3D designed unique and safe face shield provides complete protection to facial area including eyes, nose and mouth from sprays and droplets. The indigenous face shield also provides hassle free respiration and very convenient to use, the company said in a statement. Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/capable-of-producing-five-lakh-3d-designed-face-shields-every-month-iti/articleshow/76002346.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

0
,

Standardby Admin0 Comments

Dozens of researchers across the globe are racing against time to come out with a vaccine for coronavirus that has infected nearly five million people and killed over 3,30,000 globally. Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/india-will-have-to-play-key-role-in-mass-production-of-coronavirus-vaccine-france/articleshow/75940131.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

0
,

Standardby Admin0 Comments

The incubator-cum-accelerator, XHealth Innovation Lab, has been set up with an initial corpus of $50 million (nearly Rs 380 crore) for which investors have already given commitment for 60 percent of the funding, according to a source involved in the venture. https://www.moneycontrol.com/news/business/aster-dm-healthcare-lsv-capital-set-up-health-tech-incubator-with-50-million-corpus-5303861.html

0
, ,

Standardby Admin0 Comments

Recently Defence Research and Development Organisation (DRDO) has listed 35 (approximately 13 major items) technologies related to COVID-19 pandemic for manufacturing, marketing and sale as per the specifications mentioned on its website. https://www.financialexpress.com/defence/drdo-covid-technology-transfer-for-msme-manufacturing-know-more-about-the-terms-conditions/1967656/

0
,

Standardby Admin0 Comments

The Bengaluru-based company has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides Founder and Non-Executive Chairman Arun Kumar said on a post-earnings conference call, without giving any more details. Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-to-conduct-trials-in-india-for-potential-covid-19-drug/articleshow/75860443.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

0
,

Standardby Vinit Deo0 Comments

The partnership would enable free-of-cost testing for COVID-19 to a large number of people from disadvantaged and marginalised communities, using NCBS-TIFR and inStem’s high-capacity technical capabilities and skilled scientific personnel, an Azim Premji Foundation statement said. Read more at: https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/azim-premji-foundation-ncbs-instem-ink-partnership-on-enhanced-testing-for-covid-19/articleshow/75803317.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

0